Literature DB >> 10376980

Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin.

V Johanson1, L E Tisell, L Olbe, B Wängberg, O Nilsson, H Ahlman.   

Abstract

The survival of 64 consecutive patients with disseminated midgut carcinoid tumours was compared in a retrospective study with that of 25 consecutive patients with sporadic malignant endocrine pancreatic tumours treated according to similar surgical principles. The presence of hepatic metastases implied a worse prognosis in neuroendocrine tumours of pancreatic rather than midgut origin. This infers that these tumour types must be separated when treatments are evaluated.

Entities:  

Mesh：

Year:  1999        PMID： 10376980      PMCID： PMC2362356          DOI： 10.1038/sj.bjc.6690494

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  13 in total

Review 1.  Neuroendocrine carcinomas of the gastrointestinal tract.

Authors:  V E Gould; W Jao; G Chejfec; B F Banner; P Bonomi
Journal:  Semin Diagn Pathol       Date:  1984-02       Impact factor: 3.464

Review 2.  Liver Metastases.

Authors:  J H Foster; J Lundy
Journal:  Curr Probl Surg       Date:  1981-03       Impact factor: 1.909

3.  Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Authors:  R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

4.  Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.

Authors:  B Wängberg; G Westberg; U Tylén; L Tisell; S Jansson; O Nilsson; V Johansson; T Scherstén; H Ahlman
Journal:  World J Surg       Date:  1996-09       Impact factor: 3.352

5.  Cytoreductive hepatic surgery for neuroendocrine tumors.

Authors:  G P McEntee; D M Nagorney; L K Kvols; C G Moertel; C S Grant
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

Review 6.  Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.

Authors:  Y P Le Treut; J R Delpero; B Dousset; D Cherqui; P Segol; G Mantion; L Hannoun; G Benhamou; B Launois; O Boillot; J Domergue; H Bismuth
Journal:  Ann Surg       Date:  1997-04       Impact factor: 12.969

7.  The management of patients with advanced carcinoid tumors and islet cell carcinomas.

Authors:  C G Moertel; C M Johnson; M A McKusick; J K Martin; D M Nagorney; L K Kvols; J Rubin; S Kunselman
Journal:  Ann Intern Med       Date:  1994-02-15       Impact factor: 25.391

8.  Prospective study of aggressive resection of metastatic pancreatic endocrine tumors.

Authors:  S E Carty; R T Jensen; J A Norton
Journal:  Surgery       Date:  1992-12       Impact factor: 3.982

Review 9.  Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease.

Authors:  J A Norton
Journal:  Digestion       Date:  1994       Impact factor: 3.216

10.  Carcinoid syndrome. Surgical management.

Authors:  R B Galland; L H Blumgart
Journal:  Br J Hosp Med       Date:  1986-03
View more
  5 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Núria Buil-Bruna; Marion Dehez; Amandine Manon; Thi Xuan Quyen Nguyen; Iñaki F Trocóniz
Journal:  AAPS J       Date:  2016-02-23       Impact factor: 4.009

Review 3.  Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.

Authors:  Jonathan R Strosberg; George A Fisher; Al B Benson; Lowell B Anthony; Bulent Arslan; John F Gibbs; Edward Greeno; Renuka V Iyer; Michelle K Kim; William J Maples; Philip A Philip; Edward M Wolin; Dasha Cherepanov; Michael S Broder
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

4.  Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.

Authors:  Su-Jung Kim; Jin Won Kim; Sae-Won Han; Do-Youn Oh; Se-Hoon Lee; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

5.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.